Sitaksentan

Sitaksentan
(IUPAC) ime
	N-(4-chloro-3-methyl-1,2-oxazol-5-yl)-2-[2-(6-methyl-2H-1,3-benzodioxol-5-yl)acetyl]thiophene-3-sulfonamide
Klinički podaci
Identifikatori
CAS broj	184036-34-8 ; 210421-64-0 (natrijumska so)
ATC kod	C02KX03
PubChem	216235
ChemSpider	21106381
Hemijski podaci
Formula	C18H15ClN2O6S2
Mol. masa	454.906 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C18H15ClN2O6S2/c1-9-5-13-14(26-8-25-13)7-11(9)6-12(22)17-15(3-4-28-17)29(23,24)21-18-16(19)10(2)20-27-18/h3-5,7,21H,6,8H2,1-2H3 ; Key: PHWXUGHIIBDVKD-UHFFFAOYSA-N
Sinonimi	Sitaksentan; TBC-11251
Farmakokinetički podaci
Bioraspoloživost	70 to 100%
Vezivanje za proteine plazme	>99%
Metabolizam	Hepatički (CYP2C9- i CYP3A4-posredovano)
Poluvreme eliminacije	10 sati
Izlučivanje	Renalno (50 do 60%); Fekalno (40 do 50%)
Farmakoinformacioni podaci
Licenca	EU EMEA:link
Trudnoća	?
Pravni status	Samo na recept (S4) (AU) POM (UK)
Način primene	Oralno

Sitaksentan natrijum (TBC-11251) je lek za tretman plućne hipertenzije.^[4] On je bio u prodaji pod imenom Telin od strane Encisive Farmaceutikals, sve dok Pfizer nije kupio tu kompaniju februara 2008. Pfizer je dobrovoljno povukao sitaksentan sa tržišta 2010. godine zbog moguće toksičnosti jetre.^[5]

Mehanizam dejstva

Sitaksentan je mali molekul koji selektivno blokira dejstvo endotelina na endotelinskom-A (ET_A) receptoru (oko 6000 puta je potentniji u odnosu na ET_B).^[6] On pripada sulfonamidnoj klasi antagonista endotelinkog receptora.

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Barst RJ, Langleben D, Frost A et al. (2004). „Sitaxsentan therapy for pulmonary arterial hypertension”. American Journal of Respiratory Critical Care Medicine 169 (4): 441–447. DOI:10.1164/rccm.200307-957OC.
↑ „Citing liver damage, Pfizer withdraws Thelin, Associated Press, December 12, 2010”. Arhivirano iz originala na datum 2010-12-13. Pristupljeno 2014-04-05.
↑ Girgis, RE; Frost, AE; Hill, NS; Horn, EM; Langleben, D; McLaughlin, VV; Oudiz, RJ; Robbins, IM i dr.. (2007). „Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.”. Annals of the rheumatic diseases 66 (11): 1467–72. DOI:10.1136/ard.2007.069609. PMC 2111639. PMID 17472992.

Literatura

Mucke HAM (2009). „Sitaxsentan for the Oral Treatment of Pulmonary Arterial Hypertension: Benefits from Endothelin Receptor Subtype Selectivity?”. Clinical Medicine: Therapeutics 1: 111–121.
Robyn J. Barst, MD; Stuart Rich, MD, FCCP; Allison Widlitz, MS, PA; Evelyn M. Horn, MD; Vallerie McLaughlin, MD and Joyce McFarlin, RN (2002). „1860-1868”. Arhivirano iz originala na datum 2003-08-04. Pristupljeno 2014-04-05.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Barst RJ, Langleben D, Frost A et al. (2004). „Sitaxsentan therapy for pulmonary arterial hypertension”. American Journal of Respiratory Critical Care Medicine 169 (4): 441–447. DOI:10.1164/rccm.200307-957OC.

[Pfizer-5] „Citing liver damage, Pfizer withdraws Thelin, Associated Press, December 12, 2010”. Arhivirano iz originala na datum 2010-12-13. Pristupljeno 2014-04-05.

[6] Girgis, RE; Frost, AE; Hill, NS; Horn, EM; Langleben, D; McLaughlin, VV; Oudiz, RJ; Robbins, IM i dr.. (2007). „Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.”. Annals of the rheumatic diseases 66 (11): 1467–72. DOI:10.1136/ard.2007.069609. PMC 2111639. PMID 17472992.

[1]

[2]

[3]

[4]

[5]

[6]